Why Don’t Smokers Want Help to Quit? A Qualitative Study of Smokers’ Attitudes towards Assisted vs. Unassisted Quitting K Morphett, B Partridge, C Gartner, A Carter, W Hall International Journal of Environmental Research and Public Health 12 (6 …, 2015 | 95 | 2015 |
Neurobehavioral differences between Alzheimer's disease and frontotemporal dementia: a meta-analysis JL Mathias, K Morphett Journal of clinical and experimental neuropsychology 32 (7), 682-698, 2010 | 57 | 2010 |
Closing the gaps in tobacco endgame evidence: a scoping review C Puljević, K Morphett, M Hefler, R Edwards, N Walker, DP Thomas, ... Tobacco control 31 (2), 365-375, 2022 | 49 | 2022 |
Framing and scientific uncertainty in nicotine vaping product regulation: An examination of competing narratives among health and medical organisations in the UK, Australia and … DA Erku, S Kisely, K Morphett, KJ Steadman, CE Gartner International Journal of Drug Policy 78, 102699, 2020 | 43 | 2020 |
Public attitudes in A ustralia towards the claim that addiction is a (brain) disease C Meurk, B Partridge, A Carter, W Hall, K Morphett, J Lucke Drug and alcohol review 33 (3), 272-279, 2014 | 37 | 2014 |
Beliefs and self-reported practices of health care professionals regarding electronic nicotine delivery systems: a mixed-methods systematic review and synthesis DA Erku, CE Gartner, K Morphett, KJ Steadman Nicotine and Tobacco Research 22 (5), 619-629, 2020 | 35 | 2020 |
Scepticism and hope in a complex predicament: People with addictions deliberate about neuroscience C Meurk, K Morphett, A Carter, M Weier, J Lucke, W Hall International Journal of Drug Policy 32, 34-43, 2016 | 32 | 2016 |
Does the content and source credibility of health and risk messages related to nicotine vaping products have an impact on harm perception and behavioural intentions? A … DA Erku, L Bauld, L Dawkins, CE Gartner, KJ Steadman, SM Noar, ... Addiction 116 (12), 3290-3303, 2021 | 29 | 2021 |
Policy debates regarding nicotine vaping products in Australia: a qualitative analysis of submissions to a government inquiry from health and medical organisations DA Erku, K Morphett, KJ Steadman, CE Gartner International Journal of Environmental Research and Public Health 16 (22), 4555, 2019 | 25 | 2019 |
What does ‘acceptance’mean? Public reflections on the idea that addiction is a brain disease C Meurk, W Hall, K Morphett, A Carter, J Lucke BioSocieties 8, 491-506, 2013 | 25 | 2013 |
Barriers and facilitators to switching from smoking to vaping: Advice from vapers K Morphett, M Weier, R Borland, HH Yong, C Gartner Drug and alcohol review 38 (3), 234-243, 2019 | 24 | 2019 |
Smokers’ understandings of addiction to nicotine and tobacco: a systematic review and interpretive synthesis of quantitative and qualitative research D Pfeffer, B Wigginton, C Gartner, K Morphett Nicotine and tobacco research 20 (9), 1038-1046, 2018 | 24 | 2018 |
Framing tobacco dependence as a “brain disease”: Implications for policy and practice K Morphett, A Carter, W Hall, C Gartner Nicotine & Tobacco Research 19 (7), 774-780, 2017 | 24 | 2017 |
Electronic nicotine delivery systems (e-cigarettes) as a smoking cessation aid: a survey among pharmacy staff in Queensland, Australia DA Erku, CE Gartner, JT Do, K Morphett, KJ Steadman Addictive behaviors 91, 227-233, 2019 | 22 | 2019 |
Medicalisation, smoking and e-cigarettes: evidence and implications K Morphett, A Carter, W Hall, C Gartner Tobacco control 26 (e2), e134-e139, 2017 | 21 | 2017 |
Predicting vaping uptake, vaping frequency and ongoing vaping among daily smokers using longitudinal data from the International Tobacco Control (ITC) Four Country Surveys G Chan, K Morphett, C Gartner, J Leung, HH Yong, W Hall, R Borland Addiction 114, 61-70, 2019 | 20 | 2019 |
A first pass, using pre‐history and contemporary history, at understanding why Australia and England have such different policies towards electronic nicotine delivery systems … V Berridge, W Hall, S Taylor, C Gartner, K Morphett Addiction 116 (9), 2577-2585, 2021 | 16 | 2021 |
Nicotine vaping product use, harm perception and policy support among pharmacy customers in Brisbane, Australia DA Erku, CE Gartner, U Tengphakwaen, K Morphett, KJ Steadman Drug and Alcohol Review 38 (6), 703-711, 2019 | 15 | 2019 |
Nicotine vaping products as a harm reduction tool among smokers: Review of evidence and implications for pharmacy practice D Erku, CE Gartner, K Morphett, CL Snoswell, KJ Steadman Research in Social and Administrative Pharmacy 16 (9), 1272-1278, 2020 | 14 | 2020 |
A qualitative study of smokers’ views on brain-based explanations of tobacco dependence K Morphett, A Carter, W Hall, C Gartner International Journal of Drug Policy 29, 41-48, 2016 | 14 | 2016 |